Korzenik JR - Search Results

1

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. Among authors: korzenik jr. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Free article. Clinical Trial.

2

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

Korzenik JR. Korzenik JR. Gastroenterol Clin North Am. 2004 Jun;33(2):285-301, ix. doi: 10.1016/j.gtc.2004.02.009. Gastroenterol Clin North Am. 2004. PMID: 15177539 Review.

3

Sargramostim for active Crohn's disease.

Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ; Sargramostim in Crohn's Disease Study Group. Korzenik JR, et al. N Engl J Med. 2005 May 26;352(21):2193-201. doi: 10.1056/NEJMoa041109. N Engl J Med. 2005. PMID: 15917384 Free article. Clinical Trial.

4

Case records of the Massachusetts General Hospital. Case 33-2005. A 43-year-old man with lower gastrointestinal bleeding.

Korzenik J, Chung DC, Digumarthy S, Badizadegan K. Korzenik J, et al. N Engl J Med. 2005 Oct 27;353(17):1836-44. doi: 10.1056/NEJMcpc059028. N Engl J Med. 2005. PMID: 16251540 No abstract available.

5

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Siegel CA, et al. Among authors: korzenik jr. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14. Clin Gastroenterol Hepatol. 2006. PMID: 16843733

6

The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark.

Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. Kaplan GG, et al. Gut. 2007 Oct;56(10):1387-92. doi: 10.1136/gut.2007.121467. Epub 2007 May 9. Gut. 2007. PMID: 17494106 Free PMC article.

7

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.

Kaplan GG, Hur C, Korzenik J, Sands BE. Kaplan GG, et al. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1509-20. doi: 10.1111/j.1365-2036.2007.03548.x. Epub 2007 Oct 11. Aliment Pharmacol Ther. 2007. PMID: 17931345

8

Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.

Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Kaplan GG, et al. Gastroenterology. 2008 Mar;134(3):680-7. doi: 10.1053/j.gastro.2008.01.004. Epub 2008 Jan 10. Gastroenterology. 2008. PMID: 18242604

9

Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.

Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Kunitake H, et al. J Gastrointest Surg. 2008 Oct;12(10):1730-6; discussion 1736-7. doi: 10.1007/s11605-008-0630-8. Epub 2008 Aug 16. J Gastrointest Surg. 2008. PMID: 18709514

10

The risk of developing Crohn's disease after an appendectomy: a meta-analysis.

Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J. Kaplan GG, et al. Am J Gastroenterol. 2008 Nov;103(11):2925-31. doi: 10.1111/j.1572-0241.2008.02118.x. Epub 2008 Sep 4. Am J Gastroenterol. 2008. PMID: 18775018

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters